GRM2 and cognitive disorder: Low, but not high, doses of an mGlu2/3 agonist were found to be helpful in patients in the early stages of schizophrenia (Kinon et al., 2015), suggesting that strategies to enhance mGlu3 signaling may help treat cognitive disorders.